Story preview
Topics in this story
Continue reading on the publisher site for the full article.
Read on publisher →Yahoo Finance
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
44 hr. ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
Anthropic’s AI-driven discovery of a new CRISPR-like enzyme system has pressured gene-editing stocks, but the technology remains at a very early stage, while CRISPR Therapeutics already has an approved therapy and multiple clinical programs.
“The experiments are still in the queue. The PR is already live,” says one expert.
Anthropic announced this week that its Claude artificial intelligence (AI) system identified a previously unknown biological system in the DNA of viruses that infect bacteria